Association of fetuin-A levels with the progression of aortic valve calcification in non-dialyzed patients
View abstract on PubMed
Summary
This summary is machine-generated.Lower serum fetuin-A levels predict faster aortic valve calcification (AVC) progression in patients with aortic valve disease (AVD). This finding is independent of kidney function and inflammation, highlighting fetuin-A
Area Of Science
- Cardiovascular Medicine
- Biochemistry
- Nephrology
Background
- Fetuin-A is a known inhibitor of ectopic calcification.
- Aortic valve calcification (AVC) is a progressive condition associated with cardiovascular events.
- Understanding predictors of AVC progression is crucial for patient management.
Purpose Of The Study
- To investigate the relationship between baseline serum fetuin-A levels and the rate of AVC progression.
- To determine if fetuin-A levels predict major adverse clinical events (MACE) in patients with aortic valve disease (AVD).
Main Methods
- Seventy-seven non-dialyzed patients with echocardiographically proven AVD were enrolled.
- Serum fetuin-A, creatinine, calcium, lipids, and C-reactive protein were measured at baseline.
- AVC progression was quantified using multislice spiral computed tomography at baseline and after a mean follow-up of 12.6 months.
Main Results
- Serum fetuin-A levels significantly predicted AVC progression (P < 0.001) in a multifactorial analysis.
- Patients with lower baseline fetuin-A levels (< 0.72 g/L) showed a significantly higher increase in AVC scores (34.6%) compared to those with higher levels (10.0%).
- Lower fetuin-A levels were also associated with an increased risk of MACE (P = 0.03).
Conclusions
- Serum fetuin-A levels are independently associated with the progression of AVC.
- Fetuin-A levels predict MACE in patients with AVD, irrespective of renal function and inflammation.
- Fetuin-A may serve as a potential biomarker for monitoring AVC progression and cardiovascular risk.